HIV/AIDS News

HHS this week announced that it will allocate more than $1.4 billion in funding through the Ryan White HIV/AIDS Program to help people with HIV who have low incomes receive medication and care.

Two experimental HIV vaccine regimens failed to reduce infections in a 3-year trial in eastern and southern Africa compared with participants who were taking a placebo, some of whom were on oral PrEP, according to a study.

Testing HIV PrEP users for STIs every 6 months did not increase the risk for STIs compared with testing them every 3 months and could reduce the cost of PrEP programs, according to a study.

Three-quarters of people globally living with HIV are on ART, a roughly 30% increase during the last nine years, and fewer people acquired HIV in 2023 than at any point since the late 1980s, UNAIDS reported.

Despite global progress toward eliminating HIV — including a growing number of nations that have hit goals to diagnose and successfully treat patients — funding pullbacks threaten to add decades to the battle, according to a study.

Post-exposure prophylaxis for HIV remained significantly underutilized, especially in acute care settings, according to study results published in Open Forum Infectious Diseases.

Lenacapavir, an injectable antiretroviral drug approved by the FDA for HIV treatment, prevented 100% of new HIV infections among women in a phase 3 trial in Africa, demonstrating its efficacy as PrEP, Gilead Sciences said.

We checked in with CDC Director Mandy K. Cohen, MD, MPH, for an update on the agency’s efforts to modernize the nation’s disease surveillance and data systems and improve how the CDC communicates with the public and physicians.

WHO reported a “major” increase in STIs in 2022, specifically highlighting an increase in syphilis and an insufficient decline in new HIV and viral hepatitis infections.